Michelle Southey is a seasoned computational chemist with extensive experience in drug discovery and molecular modeling. Currently serving as Drug Maker in Residence at Curie.Bio since June 2024, Michelle has held various leadership positions at Evotec from May 2018 to June 2024, including VP, Head of Molecular Architects, and VP Computational Drug Discovery. Earlier roles at Evotec and Sterix (University of Bath) involved high-level scientific collaboration and problem-solving in drug development. Michelle holds a PhD in Computational Chemistry from the University of Bristol and an MChem in Chemistry from the University of Leeds, with additional studies at Georgia Institute of Technology.
This person is not in any teams
This person is not in any offices
Curie.Bio
1 followers
Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling quality dataset that enables an awesome Series A financing. In a nutshell, we want founders in control of their own company and focused on their area of expertise and creativity, while we help make the rest happen smoothly.